The villains were injectable specialty drugs like Keytruda and inpatient surgical procedures for seriously ill patients.
Stephens analyst Scott Fidel lowered the firm’s price target on Cigna (CI) to $380 from $410 and keeps an Overweight rating on the shares. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback